Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 12 results.
User Information
Export Records
  1. 1.   KIT Suppresses BRAF(V600E)-Mutant Melanoma by Attenuating Oncogenic RAS/MAPK Signaling
  2. Neiswender, James V.; Kortum, Robert L.; Bourque, Caitlin; Kasheta, Melissa; Zon, Leonard I.; Morrison, Deborah; Ceol, Craig J.
  3. Cancer Research. 2017, Nov 01; 77(21): 5820-5830.
  1. 2.   CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunity
  2. Shirota, H.; Klinman, D. M.
  3. Cancer Immunology Immunotherapy. 2011, May; 60(5): 659-669.
  1. 3.   Phenotype and functional characterization of long-term gp100-specific memory CD8(+) T cells in disease-free melanoma patients before and after boosting immunization
  2. Walker, E. B.; Haley, D.; Petrausch, U.; Floyd, K.; Miller, W.; Sanjuan, N.; Alvord, G.; Fox, B. A.; Urba, W. J.
  3. Clinical Cancer Research. 2008 14(16): 5270-5283.
  1. 4.   Upregulation of CTLA-4 by HIV-specific CD4(+) T cells correlates with disease progression and defines a reversible immune dysfunction
  2. Kaufmann, D. E.; Kavanagh, D. G.; Pereyra, F.; Zaunders, J. J.; Mackey, E. W.; Miura, T.; Palmer, S.; Brockman, M.; Rathod, A.; Piechocka-Trocha, A.; Baker, B.; Zhu, B.; Le Gall, S.; Waring, M. T.; Ahern, R.; Moss, K.; Kelleher, A. D.; Coffin, J. M.; Freeman, G. J.; Rosenberg, E. S.; Walker, B. D.
  3. Nature Immunology. 2007, Nov; 8(11): 1246-1254.
  1. 5.   CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques
  2. Hryniewicz, A.; Boasso, A.; Edghill-Smith, Y.; Vaccari, M.; Fuchs, D.; Venzon, D.; Nacsa, J.; Betts, M. R.; Tsai, W. P.; Heraud, J. M.; Beer, B.; Blanset, D.; Chougnet, C.; Lowy, I.; Shearer, G. M.; Franchini, G.
  3. Blood. 2006, Dec; 108(12): 3834-3842.
  1. 6.   Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model
  2. He, H.; Wisner, P.; Yang, G. J.; Hu, H. M.; Haley, D.; Miller, W.; O'Hara, A.; Alvord, W. G.; Clegg, C. H.; Fox, B. A.; Urba, W. J.; Walker, E. B.
  3. Journal of Translational Medicine. 2006, Jun; 4
  1. 7.   In vivo hydrodynamic delivery of cDNA encoding IL-2: Rapid, sustained redistribution, activation of mouse NK cells, and therapeutic potential in the absence of NKT cells
  2. Ortaldo, J. R.; Winkler-Pickett, R. T.; Bere, E. W.; Watanabe, M.; Murphy, W. J.; Wiltrout, R. H.
  3. Journal of Immunology. 2005, JUL 15; 175(2): 693-699.
  1. 8.   gp100(209-2M) peptide immunization of human lymphocyte antigen-A2(+) stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8(+) T cells
  2. Walker, E. B.; Haley, D.; Miller, W.; Floyd, K.; Wisner, K. P.; Sanjuan, N.; Maecker, H.; Romero, P.; Hu, H. M.; Alvord, W. G.; Smith, J. W.; Fox, B. A.; Urba, W. J.
  3. Clinical Cancer Research. 2004 10(2): 668-680.
  1. 9.   Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8(+) T-cell responses
  2. Smith, J. W.; Walker, E. B.; Fox, B. A.; Haley, D.; Wisner, K. P.; Doran, T.; Fisher, B.; Justice, L.; Wood, W.; Vetto, J.; Maecker, H.; Dols, A.; Meijer, S.; Hu, H. M.; Romero, P.; Alvord, W. G.; Urba, W. J.
  3. Journal of Clinical Oncology. 2003 21(8): 1562-1573.
  1. 10.   Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells
  2. Overwijk, W. W.; Theoret, M. R.; Finkelstein, S. E.; Surman, D. R.; de Jong, L. A.; Vyth-Dreese, F. A.; Dellemijn, T. A.; Antony, P. A.; Spiess, P. J.; Palmer, D. C.; Heimann, D. M.; Klebanoff, C. A.; Yu, Z. Y.; Hwang, L. N.; Feigenbaum, L.; Kruisbeek, A. M.; Rosenberg, S. A.; Restifo, N. P.
  3. Journal of Experimental Medicine. 2003 198(4): 569-580.
  1. 11.   Are all hypotheses generated before data analysis prospective?
  2. Urba, W. J.; Alvord, W. G.
  3. Journal of Clinical Oncology. 2002 20(6): 1431-1433.
  1. 12.   Phase I Trial of Anti-Cd3-Stimulated Cd4(+) T Cells Infusional Interleukin-2, and Cyclophosphamide in Patients With Advanced Cancer
  2. Curti, B. D.; Ochoa, A. C.; Powers, G. C.; Kopp, W. C.; Alvord, W. G.; Janik, J. E.; Gause, B. L.; Dunn, B.; Kopreski, M. S.; Fenton, R.; Zea, A.; Danskyullmann, C.; Strobl, S.; Harvey, L.; Nelson, E.; Sznol, M.; Longo, D. L.
  3. Journal of Clinical Oncology. 1998 16(8): 2752-2760.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel